Free tool
FAERS Monitor: Bylvay
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215498 or its brand name (Bylvay, Odevixibat). Reports on generic versions are filed under their own applications.
Reports
398
Serious
162
41% of reports
Hospitalization
75
Death reported
19
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pruritus106
- diarrhoea99
- off label use79
- drug ineffective39
- liver transplant36
- product dose omission issue27
- abdominal pain upper25
- hepatic enzyme increased25
- abdominal pain22
- blood bilirubin increased22
- alanine aminotransferase increased20
- bile acids increased20
- vomiting20
- nausea16
- aspartate aminotransferase increased15
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 4 |
| 2022 | 52 |
| 2023 | 48 |
| 2024 | 60 |
| 2025 | 107 |
| 2026 | 127 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,761 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| bile acids increasedSignal | 20 | 6738.7 | 4276.0 | 113,609 |
| liver transplantSignal | 36 | 528.5 | 386.4 | 18,253 |
| blood bilirubin increasedSignal | 22 | 43.1 | 28.7 | 863 |
| hepatic enzyme increasedSignal | 25 | 19.4 | 13.3 | 419 |
| alanine aminotransferase increasedSignal | 20 | 17.2 | 11.2 | 290 |
| aspartate aminotransferase increasedSignal | 15 | 14.9 | 9.1 | 182 |
| pruritusSignal | 106 | 14.6 | 12.4 | 1,352 |
| diarrhoeaSignal | 99 | 8.1 | 6.8 | 629 |
| abdominal pain upperSignal | 25 | 6.4 | 4.4 | 110 |
| abdominal painSignal | 22 | 5.0 | 3.3 | 67 |
| product dose omission issueSignal | 27 | 4.9 | 3.4 | 80 |
| off label useSignal | 79 | 4.8 | 3.9 | 242 |
| vomitingSignal | 20 | 2.2 | 1.5 | 13 |
| drug ineffective | 39 | 1.6 | 1.2 | 8 |
| nausea | 16 | 1.1 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.